Inovio Stock Story

INO
 Stock
  

USD 2.41  0.10  3.98%   

Berkeley Lights would recover faster from the current drop as its shares price went up 3.51% to Inovio Pharma's 8.33%As many rational traders are trying to avoid healthcare space, it makes sense to outline Inovio Pharma a little further and understand how it stands against Berkeley Lights and other similar entities. We are going to inspect some of the competitive aspects of both Inovio and Berkeley.
Published over two months ago
View all stories for Inovio Pharma | View All Stories

Will Berkeley Lights (NASDAQ:BLI) and Inovio Pharma (NASDAQ:INO) deliver in July?

By analyzing existing basic indicators between Inovio Pharma and Berkeley, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Berkeley with a short position in Inovio Pharma. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inovio Pharma has an asset utilization ratio of 0.83 percent. This suggests that the company is making $0.008277 for each dollar of assets. An increasing asset utilization means that Inovio Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Inovio or Aadi Biosciences is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Inovio Pharma's Liquidity

Inovio Pharma financial leverage refers to using borrowed capital as a funding source to finance Inovio Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inovio Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Inovio Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Inovio Pharma, but it might be worth checking our own buy vs. sell analysis

Correlation Between Inovio and Aadi Biosciences

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Inovio Pharma together with similar or unrelated positions with a negative correlation. For example, you can also add Aadi Biosciences to your portfolio. If Aadi Biosciences is not perfectly correlated to Inovio Pharma it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Inovio Pharma for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between INO and AADI for more information.

Exercise or conversion by David Weiner of 11875 shares of Inovio Pharma subject to Rule 16b-3

Legal trades by Inovio Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for exercise of common stock option by David Weiner, the corporate stakeholder, on 11th of August 2022. This event was filed by Inovio Pharmaceuticals In with SEC on 2022-08-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now take a look at Inovio Pharma revenue. Based on the latest financial disclosure, Inovio Pharma reported 1.77 M of revenue. This is 99.98% lower than that of the Healthcare sector and 99.76% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.98% higher than that of Inovio Pharma. As for Berkeley Lights we see revenue of 85.39 M, which is 88.51% lower than that of the Biotechnology

Sector
742.9 M
INO1.77 Million0.21
Sector742.91 Million89.5
BLI85.39 Million10.29

Does Inovio Pharma have anything more to disclose in June?

Variance is down to 38.16. It may entail a possible volatility slide.
As of the 10th of June, Inovio Pharma retains the market risk adjusted performance of (0.30), and Risk Adjusted Performance of (0.17). Inovio Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Inovio Pharma, which can be compared to its competitors. Please check out Inovio Pharma standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Inovio Pharma is priced fairly, providing market reflects its last-minute price of 1.65 per share. Please also validate Inovio Pharma total risk alpha, which is currently at (0.75) to confirm the company can sustain itself at a future point.

Our Takeaway on Inovio Pharma Investment

Whereas some other firms in the biotechnology industry are either recovering or due for a correction, Inovio Pharma may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Inovio Pharma.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Inovio Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com